Skip to main
CORT

Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics (CORT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Corcept Therapeutics Inc. demonstrates a strong positive outlook due to its projected risk-adjusted sales, which are anticipated to grow from $171 million in 2026 to a peak of $1.9 billion in 2031. The company’s strategic focus on relacorilant, particularly in the context of increasing market penetration expectations from 20% to 25% for ovarian cancer treatments, underlines its potential for significant revenue growth. Furthermore, the promising survival data from pivotal trials strengthens the probability of approval for relacorilant, indicating a solid foundation for future sales, especially with plans to support its launch with dedicated oncology sales representatives.

Bears say

Corcept Therapeutics has experienced a significant decline in its 12-month price target, dropping from prior estimates of $105 and $145 to $67 and $90 per diluted share, respectively, reflecting a negative outlook primarily due to the Complete Response Letter (CRL) received for relacorilant, which has delayed its launch for treating Cushing’s syndrome. The financial ramifications of this CRL, coupled with anticipated pricing pressures from payors affecting Korlym sales for 2026, further exacerbate concerns regarding the company’s future revenue streams and overall market performance. Additionally, the reliance on multiple valuation methods, such as NPV, EV/sales, and EV/earnings analyses, underscores the economic uncertainty surrounding projected future revenues and profitability through 2034.

Corcept Therapeutics (CORT) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corcept Therapeutics (CORT) Forecast

Analysts have given Corcept Therapeutics (CORT) a Buy based on their latest research and market trends.

According to 5 analysts, Corcept Therapeutics (CORT) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corcept Therapeutics (CORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.